| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Etoposide | Etoposide EP Impurity B | VE0010332 | View CAS 100007-56-5 |
| Etoposide | Etoposide EP Impurity C | VE008553 | View CAS 100007-53-2 |
| Etoposide | Etoposide EP Impurity D | VE0010333 | View CAS 23363-35-1 |
| Etoposide | Etoposide EP Impurity E | VE0010334 | View CAS 6559-91-7 |
| Etoposide | Etoposide EP Impurity N | VE0010335 | View |
| Etoposide | Etoposide EP Impurity O | VE0010336 | View |
| Catalogue No. | VE008553 |
| CAS No. | 100007-53-2 |
| Molecular Formula | C29H32O13 |
| Molecular Weight | 588.56 g/mol |
| Parent drug | Etoposide |
| IUPAC Name | (5R, 5aR, 8aR, 9S)-9-[[4, 6-O-[(R)-ethylidene]-a-D-glucopyranosyl]oxy]-5-(4-hydroxy-3, 5-dimethoxyphenyl)-5, 8, 8a, 9-tetrahydroisobenzofuro[5, 6-f][1, 3]benzodioxol-6(5aH)-one |
| Synonyms | a-Etoposide |
| References | Yang, J., Bogni, A., Schuetz, E. G., Ratain, M., Eileen Dolan, M., McLeod, H., … Altman, R. B. (2009). Etoposide pathway. Pharmacogenetics and Genomics, 19(7), 552–553. https://doi.org/10.1097/fpc.0b013e32832e0e7f |
| Status | In-stock |
| ListName | Etoposide EP Impurity C |
| Exclusively Supplied by Veeprho | Exclusively Supplied by Veeprho |
"*" indicates required fields
